Dietrich Mannes, Laboratory Manager, Research & Development
Boehringer Ingelheim has two main development centres in Biberach, Germany, as well as one in Ridgefield, USA, and one in Kobe, Japan. Our overriding goal is quick, efficient, cost-effective development using high-quality substances. We rely on our own research, in-licensing and indication extensions to facilitate quick registrations at authorities, successful market introductions and cost-effective, resource-efficient production. Medications are then the result of our own research conducted in Biberach on the central nervous system, respiratory tract, metabolism and thromboembolism or in Vienna on oncology. Of course, Boehringer Ingelheim has licensing projects, too. A particular focus of our work is on lifecycle management – the innovative further development of core products.